Shares of Rallybio Corp. (RLYB) are up 71% on Thursday following the announcement of a partnership with Johnson & Johnson (JNJ) aimed at advancing therapeutic approaches to mitigate the risk of fetal and neonatal alloimmune thrombocytopenia also known as FNAIT.
Jefferies Financial Group downgraded shares of Rallybio (NASDAQ:RLYB – Free Report) from a buy rating to a hold rating in a research note published on Wednesday morning, Marketbeat Ratings reports. A number of other research analysts also recently issued reports on RLYB. HC Wainwright restated a buy rating and set a $17.00 target price on […]
Rallybio Co. (NASDAQ:RLYB – Free Report) – Equities research analysts at Wedbush issued their FY2028 EPS estimates for shares of Rallybio in a report issued on Tuesday, February 6th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.88) per share for the year. Wedbush has a “Outperform” rating and a $13.00 […]
Rallybio (NASDAQ:RLYB – Get Free Report) had its price target reduced by equities researchers at Wedbush from $14.00 to $13.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush also issued estimates for Rallybio’s FY2028 earnings at ($0.88) EPS. A […]